New Drug LR12 Prevents Dangerous Plaque Buildup in Heart Stents by Calming Inflammation
TREM-1 inhibitor LR12 reduced harmful plaque formation in stents by nearly 50% without affecting healing in rabbit studies.
Summary
Researchers discovered that LR12, a new anti-inflammatory drug, can prevent dangerous plaque buildup inside heart stents. In rabbit studies, LR12 reduced harmful plaque formation by up to 49% at three months without interfering with proper stent healing. The drug works by switching immune cells called macrophages from their inflammatory state to a healing state, reducing the risk of blood clots and stent blockages that can cause heart attacks years after stent placement.
Detailed Summary
Heart stents save lives by opening blocked arteries, but they can develop new dangerous plaques over time, leading to heart attacks years later. This process, called in-stent neoatherosclerosis, affects many patients and represents a major unmet medical need.
Researchers tested LR12 (nangibotide), a drug that blocks TREM-1, an inflammation amplifier, in 40 rabbits with high-fat diets who received heart stents. Half received LR12 treatment while half got placebo, with outcomes measured at one and three months using advanced imaging.
LR12 dramatically reduced harmful plaque formation by 40.5% at one month and 48.7% at three months compared to controls. The drug also reduced plaque thickness by 31% without impairing stent healing or blood vessel lining repair. Mechanistically, LR12 shifted immune cells from inflammatory M1 macrophages to healing M2 types while reducing inflammatory markers like TNF-α and IL-6.
For longevity and cardiovascular health, this research suggests a potential breakthrough in preventing late stent complications that cause heart attacks years after initial treatment. LR12 could extend the protective benefits of stents while reducing long-term cardiovascular risk, potentially adding healthy years to patients' lives.
However, this remains early-stage animal research requiring human trials to confirm safety and effectiveness before clinical application.
Key Findings
- LR12 reduced dangerous stent plaque formation by 49% at 3 months without affecting healing
- Drug shifted immune cells from inflammatory to healing state, reducing cardiovascular risk
- Treatment lowered inflammatory markers TNF-α and IL-6 that drive heart disease
- LR12 prevented foam cell formation that contributes to atherosclerotic plaque buildup
Methodology
Controlled study in 40 male rabbits fed high-fat diets, randomized to LR12 or placebo after stent placement. Advanced optical coherence tomography imaging assessed outcomes at 1 and 3 months with comprehensive biomarker analysis.
Study Limitations
Animal study results may not translate to humans. Long-term safety and efficacy in human populations unknown. Study limited to male rabbits with artificially induced atherosclerosis.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.